<DOC>
	<DOCNO>NCT01929265</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design determine efficacy safety chemoimmunotherapy combination Bendamustine + Rituximab patient advance untreated Indolent non Follicular non-Hodgkin Lymphomas ( INFL ) .</brief_summary>
	<brief_title>A Phase II Study Bendamustine Combination With Rituximab Initial Treatment Patients With Indolent Non-follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This prospective , multicenter phase II trial design determine efficacy safety chemoimmunotherapy combination Bendamustine + Rituximab patient advance untreated Indolent non Follicular non-Hodgkin Lymphomas ( INFL ) . The study include induction phase consolidation phase .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form 2 . Histological ( bone marrow lymph node biopsy ) proven diagnosis Bcell CD20 positive nonfollicular NHL accord REAL/WHO Classification : i. small lymphocytic lymphomaSLL ( bone marrow lymph node biopsy ii . lymphoplasmacytic/citoid lymphoma/ Waldenstrom macroglobulinemia ( bone marrow lymph node biopsy ) iii . nodal marginal zone lymphoma ( lymph node biopsy ) 3 . Untreated patient 4 . Stage III IV stage II three involve site 5 . Presence least one follow criterion definition active disease : 1 . Systemic symptoms 2 . Hemoglobin le 10 g/dL ( due lymphoma ) 3 . Platelets le 100 x 10 9/L ( due lymphoma ) 4 . Diffuse bone marrow infiltrate 5 . Lymphocyte double time le 12 month ( leukemic case ) 6 . Bulky disease ( &gt; 7 cm ) 6 . Aged 18 75 Life expectancy &gt; 6 month 7 . ECOG performance status 02 8 . LVEF ≥45 % FS ≥37 % 9 . ANC ≥1 x 10 9/l Platelets count ≥75 x 10 9/l , unless due bone marrow involvement follicular lymphoma 10 . Creatinine 1.5 x ULN 11 . Conjugated bilirubin 2 x ULN 12 . Alkaline phosphatase transaminases 2 x ULN 13 . Written inform content 1 . Patients diagnosis marginal zone lymphoma splenic MALT origin 2 . Patients diagnosis typical Chronic Lymphocytic Leukemia ( CLL ) 3 . Men agree take adequate contraceptive precaution least 6 month cessation therapy 4 . History malignancy within 3 year prior study entry except : adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage , localized prostate cancer treat surgically curative intent ; good prognosis DCIS breast treat lumpectomy alone curative intent 5 . Medical condition require long term use ( &gt; 1 month ) systemic corticosteroid 6 . Active bacterial , viral , fungal infection require systemic therapy 7 . Concurrent medical condition might exclude administration therapy 8 . Cardiac insufficiency ( NYHA grade III/IV ) 9 . Myocardial infarction within 6 month entry study 10 . Severe chronic obstructive pulmonary disease hypoxemia 11 . Severe diabetes mellitus difficult control adequate insulin therapy 12 . Hypertension difficult control 13 . Impaired renal function creatinine clearance &lt; 30 ml/min 14 . HIV positivity 15 . HBV positivity exception patient HbsAg negative Ab antiHbcore positive ( patientes need receive prophylaxis Lamivudine ) 16 . HCV positivity exception patient HCV RNA negative . 17 . CNS involvement lymphoma 18 . Participation time another study investiogational drug use 19 . Known hypersensitivity anaphylactic reaction murine antibody proteins 20 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent 21 . Women pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>INFL</keyword>
	<keyword>Indolent non-follicular</keyword>
	<keyword>untreated INFL</keyword>
</DOC>